- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
- Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
- Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
More ▼
Key statistics
On Thursday, Arcturus Therapeutics Holdings Inc (ARCT:NMQ) closed at 33.77, -22.92% below its 52-week high of 43.81, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.04 |
---|---|
High | 33.84 |
Low | 32.00 |
Bid | 31.71 |
Offer | 34.70 |
Previous close | 32.86 |
Average volume | 603.73k |
---|---|
Shares outstanding | 26.92m |
Free float | 24.54m |
P/E (TTM) | -- |
Market cap | 908.93m USD |
EPS (TTM) | -1.16 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼